Literature DB >> 20689501

Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.

Anthony E Fiore1, Timothy M Uyeki, Karen Broder, Lyn Finelli, Gary L Euler, James A Singleton, John K Iskander, Pascale M Wortley, David K Shay, Joseph S Bresee, Nancy J Cox.   

Abstract

This report updates the 2009 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for the prevention and control of influenza (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2009;58[No. RR-8] and CDC. Use of influenza A (H1N1) 2009 monovalent vaccine---recommendations of the Advisory Committee on Immunization Practices [ACIP], 2009. MMWR 2009;58:[No. RR-10]). The 2010 influenza recommendations include new and updated information. Highlights of the 2010 recommendations include 1) a recommendation that annual vaccination be administered to all persons aged >or=6 months for the 2010-11 influenza season; 2) a recommendation that children aged 6 months--8 years whose vaccination status is unknown or who have never received seasonal influenza vaccine before (or who received seasonal vaccine for the first time in 2009-10 but received only 1 dose in their first year of vaccination) as well as children who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine regardless of previous influenza vaccine history should receive 2 doses of a 2010-11 seasonal influenza vaccine (minimum interval: 4 weeks) during the 2010--11 season; 3) a recommendation that vaccines containing the 2010-11 trivalent vaccine virus strains A/California/7/2009 (H1N1)-like (the same strain as was used for 2009 H1N1 monovalent vaccines), A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens be used; 4) information about Fluzone High-Dose, a newly approved vaccine for persons aged >or=65 years; and 5) information about other standard-dose newly approved influenza vaccines and previously approved vaccines with expanded age indications. Vaccination efforts should begin as soon as the 2010-11 seasonal influenza vaccine is available and continue through the influenza season. These recommendations also include a summary of safety data for U.S.-licensed influenza vaccines. These recommendations and other information are available at CDC's influenza website (http://www.cdc.gov/flu); any updates or supplements that might be required during the 2010-11 influenza season also will be available at this website. Recommendations for influenza diagnosis and antiviral use will be published before the start of the 2010-11 influenza season. Vaccination and health-care providers should be alert to announcements of recommendation updates and should check the CDC influenza website periodically for additional information.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689501

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  550 in total

1.  The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant?

Authors:  Sesquile Ramon; Steven F Baker; Julie M Sahler; Nina Kim; Eric A Feldsott; Charles N Serhan; Luis Martínez-Sobrido; David J Topham; Richard P Phipps
Journal:  J Immunol       Date:  2014-11-12       Impact factor: 5.422

2.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

Review 3.  The contribution of animal models to the understanding of the host range and virulence of influenza A viruses.

Authors:  Christopher D O'Donnell; Kanta Subbarao
Journal:  Microbes Infect       Date:  2011-01-27       Impact factor: 2.700

4.  Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants.

Authors:  Carl T D'Angio; Roy J Heyne; Shahnaz Duara; Lucy C Holmes; T Michael O'Shea; Hongyue Wang; Dongwen Wang; Pablo J Sánchez; Robert C Welliver; Rita M Ryan; Kenneth C Schnabel; Caroline B Hall
Journal:  Pediatr Infect Dis J       Date:  2011-07       Impact factor: 2.129

5.  Low influenza vaccination rates among child care workers in the United States: assessing knowledge, attitudes, and behaviors.

Authors:  Marie A de Perio; Douglas M Wiegand; Stefanie M Evans
Journal:  J Community Health       Date:  2012-04

6.  Sometimes, more is better.

Authors:  Edgar Turner Overton
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

7.  The influence of altruism on influenza vaccination decisions.

Authors:  Eunha Shim; Gretchen B Chapman; Jeffrey P Townsend; Alison P Galvani
Journal:  J R Soc Interface       Date:  2012-04-11       Impact factor: 4.118

8.  The expected emotional benefits of influenza vaccination strongly affect pre-season intentions and subsequent vaccination among healthcare personnel.

Authors:  Mark G Thompson; Manjusha J Gaglani; Allison Naleway; Sarah Ball; Emily M Henkle; Leslie Z Sokolow; Beth Brennan; Hong Zhou; Lydia Foster; Carla Black; Erin D Kennedy; Sam Bozeman; Lisa A Grohskopf; David K Shay
Journal:  Vaccine       Date:  2012-04-01       Impact factor: 3.641

9.  Influenza update: a review of currently available vaccines.

Authors:  Lisa R Clayville
Journal:  P T       Date:  2011-10

Review 10.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.